You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME/CE

AAP Endorses CDC Guideline to Prevent Perinatal GBS

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Hien T. Nghiem, MD
  • CME/CE Released: 8/4/2011
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/4/2012
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, obstetricians, and other specialists who care for newborns at risk for perinatal group B streptococcal disease.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Report the preferred medication for intrapartum antibiotic prophylaxis.
  2. Report the revised algorithm for the care of newborn infants.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laurie Barclay, MD

    Freelance writer and reviewer, Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Editor(s)

  • Jacqueline A. Hart, MD

    is a freelance clinical editor for Medscape, LLC

    Disclosures

    Disclosure: Jacqueline A. Hart, MD, has disclosed no relevant financial relationships.

CME Author(s)

  • Hien T. Nghiem, MD

    Assistant Clinical Professor, Associate Residency Program Director, University of California, Irvine-Orange, Department of Family Medicine

    Disclosures

    Disclosure: Hien T. Nghiem, MD, has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Sarah Fleischman

    CME Program Manager, Medscape, LLC

    Disclosures

    Disclosure: Sarah Fleischman has disclosed no relevant financial relationships.

Nurse Planner

  • Laurie E. Scudder, DNP, NP

    Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

    Disclosures

    Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity, Medscape Education Clinical Briefs has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins September 1, 2010. Term of approval is for 1 year from this date. Each issue is approved for .25 Prescribed credits. Credit may be claimed for 1 year from the date of this issue.

    Note: Total credit is subject to change based on topic selection and article length.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Accreditation of this program does not imply endorsement by either Medscape, LLC or ANCC.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape Education encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME/CE

AAP Endorses CDC Guideline to Prevent Perinatal GBS

Authors: News Author: Laurie Barclay, MD CME Author: Hien T. Nghiem, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME/CE Released: 8/4/2011

Valid for credit through: 8/4/2012

processing....

Clinical Context

Initially, the Centers for Disease Control and Prevention (CDC) guidelines for the prevention of perinatal group B streptococcal (GBS) disease were published in 1996 and revised again in 2002. Since then, the incidence of early-onset GBS disease in neonates has decreased by an estimated 80%. However, in 2010, GBS disease remained the leading cause of early-onset neonatal sepsis.

The CDC issued revised guidelines in 2010. These revised and comprehensive guidelines, which the American Academy of Pediatrics (AAP) has endorsed, reaffirm the major prevention strategy — universal antenatal GBS screening and intrapartum antibiotic prophylaxis (IAP) for culture-positive and high-risk women — and include new recommendations for laboratory methods for identification of GBS colonization during pregnancy, algorithms for screening and intrapartum prophylaxis for women with preterm labor and premature rupture of membranes, updated prophylaxis recommendations for women with a penicillin allergy, and a revised algorithm for the care of newborn infants.

The purpose of this policy statement is to review and discuss the differences between the 2002 and 2010 CDC guidelines that are most relevant for the practice of pediatrics.

Study Synopsis and Perspective

The AAP has issued a policy statement, reported online August 1 in Pediatrics, on preventing perinatal GBS disease. The policy statement was intended to review and discuss the differences between the 2002 and 2010 CDC guidelines that are most relevant to pediatric practice.

"In 2002, the CDC published revised guidelines that recommended universal antenatal GBS screening; the AAP endorsed these guidelines and published recommendations based on them in the 2003 Red Book," write Carol J. Baker, MD, and colleagues from the AAP. "The CDC issued revised guidelines in 2010 based on evaluation of data generated after 2002. These revised and comprehensive guidelines, which have been endorsed by the AAP, reaffirm the major prevention strategy—universal antenatal GBS screening and intrapartum antibiotic prophylaxis for culture-positive and high-risk women—and include new recommendations for laboratory methods for identification of GBS colonization during pregnancy, algorithms for screening and intrapartum prophylaxis for women with preterm labor and premature rupture of membranes, updated prophylaxis recommendations for women with a penicillin allergy, and a revised algorithm for the care of newborn infants."

Specific recommendations in the AAP policy statement for the care of newborn infants include the following:

  • Full diagnostic evaluation, including lumbar puncture, and empiric antimicrobial treatment are indicated for all newborn infants with signs of sepsis (AII recommendation).
  • Limited diagnostic evaluation without lumbar puncture and empiric antimicrobial treatment are indicated for all well-appearing newborn infants of mothers diagnosed with chorioamnionitis by their obstetrician (AII).
  • Newborn infants of all women who received adequate IAP require only routine care and observation in the hospital for 48 hours (B III). They may be discharged as early as 24 hours after birth, with follow-up care by a clinician within 48 to 72 hours, if they meet other discharge criteria, including term birth and ready access to medical care (CII). Adequate IAP includes penicillin (preferred), ampicillin, or cefazolin (in penicillin-allergic women at low risk for anaphylaxis) for at least 4 hours before delivery.
  • Observation only for 48 hours is required for well-appearing term newborn infants whose mothers received no or inadequate IAP and had rupture of membranes for less than 18 hours (BIII).
  • "Limited evaluation" (blood culture and complete blood cell count with differential and platelets at birth) and observation for at least 48 hours are indicated for well-appearing term infants born to women with no or inadequate IAP and rupture of membranes for 18 or more hours before delivery (BIII).
  • All preterm infants of mothers with no or inadequate IAP should undergo limited evaluation and observation for at least 48 hours (BIII).

Pediatrics. Published online August 1, 2011.

Related Link

The California Perinatal Quality Care Collaborative provides a downloadable delivery room management toolkit, revised in July 2011, for the Prevention of Perinatal Group B Streptococcus Disease.

Study Highlights

  • Universal culture-based screening for GBS occurs at 35 to 37 weeks' gestation.
  • Options for GBS identification from culture of maternal vaginal/rectal swabs have been expanded to include a positive identification from chromogenic agar media.
  • Identification of GBS directly by nucleic acid amplification tests, such as commercially available polymerase chain reaction assays, can also be used after broth enrichment if laboratories have validated the performance of nucleic acid amplification tests and instituted appropriate quality controls (CII).
  • Recommendations for IAP include the following:
    • Penicillin remains the agent of choice for IAP, and ampicillin is an acceptable alternative (AI).
    • Penicillin-allergic women who do not have a history of anaphylaxis, angioedema, respiratory distress, or urticaria after administration of penicillin or a cephalosporin should receive cefazolin (BII).
    • Penicillin-allergic women at high risk for anaphylaxis should receive clindamycin if the GBS isolate is susceptible or vancomycin if the GBS isolate is intrinsically resistant to clindamycin (CIII).
    • The definition of adequate IAP has been clarified to be at least 4 hours of penicillin, ampicillin, or cefazolin.
    • The initial intravenous dose of penicillin is 5 million units; for ampicillin and cefazolin, the initial dose is 2 g (AIII).
  • Recommendations for the care of newborn infants include the following:
    • All newborn infants with signs of sepsis should undergo a full diagnostic evaluation (including a lumbar puncture) and receive empiric antimicrobial therapy (AII).
    • Empiric antimicrobial therapy is typically ampicillin and gentamicin.
    • All well-appearing newborn infants born to women given a diagnosis of chorioamnionitis by their obstetric provider should undergo a limited diagnostic evaluation (no lumbar puncture) and receive empiric antimicrobial therapy (AII).
    • For all women who received adequate IAP defined as penicillin (preferred), ampicillin, or cefazolin (penicillin-allergic women at low risk for anaphylaxis) for 4 or more hours before delivery, their newborn infants require only routine care and observation in the hospital for 48 hours (BIII). If these infants meet other discharge criteria, discharge from the hospital can occur as early as 24 hours after birth with follow-up care by a care provider within 48 to 72 hours (CII).
    • Well-appearing term newborn infants whose mothers received no or inadequate IAP (including clindamycin or vancomycin) and had rupture of membranes for less than 18 hours require only observation for 48 hours (BIII).
    • Well-appearing term infants born to women with no or inadequate IAP and rupture of membranes for 18 or more hours before delivery should undergo a "limited evaluation" (ie, blood culture and complete blood cell count with differential and platelets at birth) and observation for at least 48 hours (BIII).
    • All preterm infants born to women with no or inadequate IAP should undergo a limited evaluation and observation for at least 48 hours (BIII).

Clinical Implications

  • Penicillin remains the agent of choice for IAP, and the definition of adequate IAP is administration of at least 4 hours of penicillin, ampicillin, or cefazolin.
  • All newborn infants with signs of sepsis should undergo a full diagnostic evaluation. However, limited evaluation is warranted for well-appearing newborn infants born to women with a diagnosis of chorioamnionitis and to women with no or inadequate IAP and rupture of membranes for 18 or more hours before delivery, and all preterm infants born to women with no or inadequate IAP.

CME Test

  • Print